These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 12804051

  • 1. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
    Bernhardt P, Ahlman H, Nilsson O, Benjegård SA, Forssell-Aronsson E.
    Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J, Abós MD, Prats E, García F, Razola P.
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract] [Full Text] [Related]

  • 6. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB, Nilsson O, Bejegård SA, Kölby L, Bernhardt P, Mölne J, Hashemi SH, Wängberg B, Tisell LE, Ahlman H.
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 111In-octreotide scintigraphy in small cell lung cancer.
    Semprebene A, Ferraironi A, Franciotti G, Venturo I, Giunta S, Lopez M, Maini CL.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Mäcke H, de Jong M.
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
    Adrian HJ, Dörr U, Bach D, Bihl H.
    Horm Metab Res Suppl; 1993 Dec; 27():18-23. PubMed ID: 8330868
    [Abstract] [Full Text] [Related]

  • 18. Peptide receptor imaging and therapy.
    Kwekkeboom D, Krenning EP, de Jong M.
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP.
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.